drugset / Trial / NCT00575588

52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension Period

NCT00575588 ↗

Phase 3 Completed 891 enrolled AstraZeneca Bristol-Myers Squibb · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Saxagliptin is a new investigational medication being developed for treatment of type 2 diabetes. This study is designed to assess the efficacy and tolerability of saxagliptin in addition to metformin and compare to sulphonylurea in addition with metformin.

Timeline

Start
2007-12
Primary completion
2009-08
Completion
2010-08

Outcome

Met primary endpoint

paper Saxagliptin was noninferior to glipizide in lowering HbA1c. PMID 24397584 ↗

release “ONGLYZA 5 mg to existing metformin therapy achieved the primary objective of demonstrating non-inferiority compared to the addition of titrated glipizide” bms.com ↗

release “the addition of ONGLYZA ™ (saxagliptin) 5 mg to existing metformin therapy achieved the primary objective of demonstrating non-inferiority compared to the addition of titrated glipizide” bms.com ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Glipizide Small molecule 5 mg —
Subject Glipizide Small molecule 20 mg —
Subject SAXAGLIPTIN ANHYDROUS Small molecule 5 mg —
Background Metformin Small molecule — —